Navigation Links
Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results
Date:5/7/2008

le notes, and warrants. The Company also expects to receive an additional $5 million in gross proceeds from an additional sale of securities to the purchaser of the Series E preferred stock and 13.5% convertible senior notes prior to July 4, 2008, provided adequate shares are available for issuance of such securities at that time.

"In the second quarter we expect to see the positive financial impact of our strategy to focus resources on our late-stage development products and growing Zevalin sales. With our commercial team now in place to support Zevalin, we expect revenues to continue to increase over the next few quarters," said James A. Bianco, M.D., President and CEO of CTI. "In addition, over the last two quarters, we have been successful in cleaning up our balance sheet, retiring or exchanging approximately 74 percent of current debt and preferred securities. With the majority of the investments in OPAXIO and pixantrone behind us we look forward to the review of the MAA for OPAXIO and to final results of the pixantrone pivotal trial."

Recent Highlights

o Announced that the Company selected and received a positive opinion

from the European Medicines Agency (EMEA) on the new brand name

OPAXIO(TM) (paclitaxel poliglumex), which replaces the name XYOTAX(TM)

o Announced that the EMEA accepted for review CTI's Marketing

Authorization Application (MAA) for OPAXIO for first-line treatment of

patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern

Cooperative Oncology Group) performance status 2 (PS2)

o Announced completion of enrollment in the phase III EXTEND (PIX301)

clinical trial of pixantrone (BBR 2778) for patients with relapsed

diffuse large B-cell non-Hodgkin's lymphoma (NHL)

o Announced the appointment of Craig W. Philips, most recently Vice

President and General Manager of Bayer Healthcare Oncology, as

president of
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
5. Profarmas Gross Revenues Reached R$ 702.6 Million in the 1st Quarter 2008, a 26.5% Growth Over the Same Period Last Year
6. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
7. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
8. MEDRAD(R) Revenues Grow 10 Percent in 2007
9. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
10. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
11. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... 27, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. , ... health-insurance clients, which have seasonal ramp-ups that require additional ... November 2014 through February 2015. As more consumers become ...
(Date:7/27/2014)... July 27, 2014 Discount-Dress.com is a ... products for its current and prospective customers. Each of ... Additionally, it has a team of considerate designers; they ... offering perfect dress solutions. , Recently, the firm ... dresses . To top it all off, these brand-new ...
(Date:7/27/2014)... OH (PRWEB) July 27, 2014 Wright ... Louisiana has filed a GranuFlo lawsuit against ... clinics in Louisiana over the recalled dialysis drugs GranuFlo ... state’s Medicaid program by not disclosing the heart attack ... lawsuit contends that Fresenius notified its own clinics, practitioners ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Dr. Rob Agosto, ... Companies since 2006 and had until recently been caring for ... has joined Dr. Chris Steacy, DC at Sport and Spine ... , “For many years, the patients of Columbia have lived ... expertise of Dr. Steacy. We worked to ...
(Date:7/27/2014)... According to the 3-Week Diet system review recently updated ... help both men and women lose weight naturally without medications. ... now by Vkool, was developed by Brian Flatt, a nutrition ... 3-Week Diet system, many people have used it to find ... hips, belly, and buttocks. , The 3-Week Diet system ...
Breaking Medicine News(10 mins):Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:New Cocktail Party Dresses From Leading Online Supplier Discount-Dress.com Receive National Attention 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5Health News:Sport and Spine Rehab of Columbia Announces the Addition of Dr. Rob Agosto, Doctor of Physical Therapy to Its Clinical Team 2Health News:3-Week Diet System Review Exposes Brian Flatt's Weight Loss Methods – Vkool.com 2
... DALLAS, Jan. 12 Affiliated Computer Services, Inc. (NYSE: ... provide Regence with Health Savings Account (HSA) administration services ... counties of Washington. Regence members will be offered the ... the addition of Regence, the largest health insurer in ...
... 12 , - Small ... , With the introduction of ... messaging device, NEC sets new standards in,mobile communications and ... innovations. , (Photo: http://www.newscom.com/cgi-bin/prnh/20090112/333834 ...
... publication of its kind aimed at healthcare fraud ... (HCI), a Verisk HealthCare company and a provider ... solutions for healthcare claims payors, announced today that ... Profiler Magazine is the nation,s ...
... Jan. 12 Wyeth Pharmaceuticals, a division of Wyeth ... announced that the companies have entered into a worldwide ... based on Santaris Pharma,s proprietary Locked Nucleic Acid (LNA) ... microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader ... patients, today announced preliminary,unaudited record fourth quarter and ... Fourth quarter 2008 revenue improved ... of approximately $3.8 million, compared with $2.7 million ...
... to Drive Real-Time Pharmacy Utilization Management DecisionsNEWPORT ... The TriZetto Group, Inc. and Sanovia Corporation ... offer the market,s first platform that integrates ... automate prior-authorizations of medications and help plans ...
Cached Medicine News:Health News:ACS to Provide HSA Product to Regence; ACS HSA Solution Now Offered by Blue Cross Blue Shield Plans in 28 States 2Health News:NEC's new M155 Messenger Sets New Standards in Mobile Messaging 2Health News:HealthCare Insight(R) Launches Industry Fraud Magazine 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 3Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 4Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 2Health News:Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue 3Health News:TriZetto, Sanovia Join Forces to Offer First Integrated Platform That Helps Payers Control Pharmacy Costs 2Health News:TriZetto, Sanovia Join Forces to Offer First Integrated Platform That Helps Payers Control Pharmacy Costs 3
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
(Date:7/24/2014)... 2014  Mettler-Toledo International Inc. (NYSE: MTD ... below are the highlights: , Sales in ... with the prior year. Reported sales increased 5% which ... earnings per diluted share as reported (EPS) were $2.49, ... Adjusted EPS was $2.57, an increase of 9% over ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14
... by Novel, Motion Picture , , DENVER, June 22 ... a couple who conceives a child to save the life of ... release of the new movie starring Cameron Diaz on Friday. , ... B. Schoolcraft, the Nashes were able to select an embryo that ...
... , Findings point to new treatment options and research directions ... and treatment may offer a new therapeutic option for many ... bladder condition affecting as many as 8 million women and ... providers who treat them have long noticed a correlation between ...
Cached Medicine Technology:Inspiration for 'My Sister's Keeper' Speaks Out 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4
... 80 mm. Grooved buckle. Size: 2.3 x 4.0 ... original Scleral Sponge II line designed by Harvey ... closed cell sponge which is non-toxic and non-antigenic. ... scleral intrusion. These implants are packaged sterile and ...
For use with E5381 700 Circling Band (240 style)....
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 12.0 mm....
For use with E5381 600 Circling Band (40 style)....
Medicine Products: